PXT3003 Phase III Results Published: A Milestone for Multimodal Therapy in CMT1A
Updated: 8 hours ago
Scientific Insights | Clinical Research | Multimodal Therapeutics
The publication of positive Phase III clinical results for PXT3003 in the peer-reviewed journal iScience marks an important milestone in the development of multimodal therapies for Charcot-Marie-Tooth disease type 1A (CMT1A).
PXT3003 is a pioneering, systems-biology-designed combination of three repurposed compounds — baclofen, naltrexone and D-sorbitol — administered together at low doses. Originally conceived and developed at Pharnext, this therapeutic approach has progressed from early experimental research to international Phase III clinical development.
The newly published Chinese trial provides further clinical evidence supporting this approach and brings the program another step closer to a potential therapeutic option for patients.
A significant clinical milestone
Published in iScience in September 2026, the randomized, double-blind, placebo-controlled Phase III trial evaluated PXT3003 in 176 patients with CMT1A across 25 clinical centers in China, over 15 months.
The study met its primary efficacy endpoint, demonstrating a statistically significant improvement in the Overall Neuropathy Limitations Scale (ONLS) compared with placebo.
At month 15:
Mean ONLS change was −0.268 with PXT3003 versus +0.013 with placebo.
The adjusted between-group difference was −0.249 points (95% CI: −0.467 to −0.030; p = 0.0257).
Additional statistically significant improvements were reported in the ONLS leg subscore and ankle dorsiflexion strength.
PXT3003 demonstrated a generally favorable safety and tolerability profile, comparable to placebo.
These results provide encouraging evidence of functional benefit in a slowly progressive neurological condition for which therapeutic options remain extremely limited.
Why this matters for patients
CMT1A is the most common form of inherited Charcot-Marie-Tooth neuropathy. It is associated with overexpression of the PMP22 gene, peripheral nerve dysfunction, progressive muscle weakness, sensory impairment and increasing limitations in everyday activities.
For people living with CMT1A, functions such as walking, maintaining balance, climbing stairs and performing routine activities can become progressively more difficult.
There is currently no approved disease-modifying therapy for CMT1A.
The Chinese Phase III findings are therefore particularly meaningful because they concern functional limitations that matter to patients, rather than relying exclusively on laboratory or biological measurements.
The improvements observed in lower-limb function and ankle dorsiflexion strength are encouraging.
PXT3003: a pioneering Multimodal Therapy (MMT)
Most conventional drug-development strategies seek to intervene at a single molecular target.
Multimodal Therapy (MMT) takes a different approach: it combines complementary pharmacological activities to influence several interconnected biological mechanisms underlying a disease.
PXT3003 illustrates this principle through a low-dose combination of three existing compounds:
The combination was originally identified using systems-biology, network-pharmacology approaches, and early AI approaches, with the aim of addressing disease processes associated with PMP22 overexpression, abnormal myelination and peripheral nerve dysfunction.
Preclinical research provided evidence supporting the biological rationale for combining these compounds. Subsequent clinical trials advanced the concept into late-stage development.
The publication of a positive Phase III primary-endpoint result in CMT1A is an important proof point for the potential of rationally designed multimodal therapeutics.
It also highlights both the opportunities and the scientific challenges of translating complex, network-based pharmacology into measurable clinical benefit.
A development journey closely connected to Tangramed's leadership
The PXT3003 program has particular significance for Tangramed.
Members of Tangramed's current scientific leadership, including Daniel Cohen, Jinchao Yu, and Rodolphe Hajj, played direct roles in the original design, experimental development and clinical advancement of PXT3003 during their tenure at Pharnext.
Their contributions helped bring the three-compound combination from early systems-biology research and preclinical validation through international clinical development, including late-stage Phase III studies.
This experience provides an important foundation for Tangramed's present scientific philosophy: complex diseases may require therapeutic strategies designed to address multiple interacting biological mechanisms.
Today, Tangramed builds on this accumulated expertise through AI-enabled network pharmacology, experimental biology and rational multimodal therapy design.
The Chinese Phase III study itself was conducted by Chinese investigators and development partners, independently of Tangramed.
From positive Phase III evidence toward regulatory evaluation
The latest publication adds important evidence to an extensive international clinical-development history.
Earlier PXT3003 trials generated encouraging evidence of clinical activity, although the subsequent multinational PREMIER confirmatory Phase III study did not meet its primary efficacy endpoints. The positive Chinese Phase III findings therefore add important new evidence.
In China, PXT3003 — also developed under the identifier CMI1808 — has progressed to the marketing-authorization review stage.
The publication of a positive Phase III study, together with the ongoing regulatory review, represents a meaningful step toward the possibility of a new treatment option for people living with CMT1A.
For patients and families who have waited many years for therapeutic progress, such advances offer renewed grounds for cautious optimism.
Looking ahead
PXT3003 demonstrates how a rationally designed combination of existing molecules can be advanced through a demanding clinical-development pathway.
For Tangramed, this milestone reinforces a conviction shaped by years of practical scientific experience: multimodal therapeutic design can be a valuable strategy for addressing the biological complexity of neurological and other difficult-to-treat diseases.
Above all, the goal remains to translate rigorous scientific innovation into meaningful improvements in patients' lives.
PXT3003 remains an investigational therapy for CMT1A, and positive Phase III results do not themselves constitute marketing authorization.